

Dual Mobility for young patients

Dr Arnaud FIQUET

Lunch symposium St Petersburg 28th Sept. 2018



What is the challenge for young patients ?

- 1 – THA which allows high activities without risk of dislocation
- 2 – THA with very long-term survivorship

THA which allows high activities without risk of dislocation

Dislocation rates with DM Primary THA

0.09 % or 1/1100

LECLERCQ S, EL BLIDI S, AUBRIOT JH : Traitement de la luxation récidivante de prothèse totale de hanche par le cotyle de Bousquet. A propos de 13 cas. Rev Chir Orthop, 1995, 81, 389-394.

0.7 % or 1/139

FARIZON F, DELAVISON R, AZOULAI JJ, BOUSQUET G : Results with a cementless alumina coated cup with dual mobility. Int Orthop, 1998, 22, 219-224.

0.0 % fu 15 years


R. Philippot, F. Farizon, J.-P. Camilleri, B. Boyer, G. Derhi, J. Bonnan, M.H. Fessy, F. Lecuire
Étude d'une série de 438 cupules non cimentées à double mobilité
Survival of dual mobility socket with a mean 17 years follow-up
Revue de Chirurgie Orthopédique, Vol 94 - N° 1 - 2008

THA with very long-term survivorship

Cementless THA with a very low wear bearing

- the metal-metal with the problematic ions metallic
- the ceramic-ceramic THA despite the difficulties managing ceramic fractures and the high rate of creaking

THA with very long-term survivorship



THA with very long-term survivorship

The 2018 Annual Report of the English Register has been published.

It confirms for the POLARSTEM / R3 at 7-year a revision rate of 0.97%, ie the lowest rate of all THA in the UK, Welsh, Northern Ireland and UK markets. 'Isle of man...

Uncemented									
Accolade / Trident	26,073	66 (59-73)	44	0.95 (0.84-1.08)	1.91 (1.75-2.09)	2.61 (2.41-2.83)	3.13 (2.89-3.38)	4.46 (4.04-4.92)	5.24 (4.37-6.28)
Corail / Duraloc Cementless Cup	4,053	70 (64-75)	39	0.77 (0.54-1.09)	1.71 (1.35-2.16)	2.51 (2.07-3.06)	3.60 (3.05-4.25)	5.58 (4.83-6.43)	9.69 (8.27-11.35)
Corail / Pinnacle	137,857	66 (59-73)	45	0.79 (0.75-0.84)	1.60 (1.53-1.67)	2.44 (2.34-2.53)	3.64 (3.50-3.77)	5.96 (5.72-6.22)	
Corail / Trilogy	3,030	68 (61-74)	40	0.65 (0.41-1.01)	1.15 (0.82-1.62)	1.65 (1.23-2.21)	2.23 (1.71-2.90)	3.45 (2.65-4.49)	4.53 (3.24-6.32)
Corail / ASR Resurfacing Cup	2,633	61 (54-67)	54	1.07 (0.74-1.54)	7.51 (6.56-8.59)	23.40 (21.81-25.09)	35.48 (33.64-37.38)	43.54 (41.57-45.57)	
Corail / Pinnacle Gription	6,089	67 (58-75)	40	1.00 (0.77-1.30)	1.77 (1.39-2.24)	2.21 (1.68-2.89)	2.97 (2.08-4.22)		
Furlong HAC Stem / CSF	17,173	69 (62-76)	40	1.06 (0.92-1.23)	1.76 (1.58-1.98)	2.15 (1.94-2.39)	2.67 (2.43-2.94)	3.60 (3.30-3.94)	5.05 (4.47-5.71)
Furlong HAC Stem / Furlong HAC CSF Plus	22,253	66 (59-73)	45	1.13 (1.00-1.28)	1.84 (1.66-2.03)	2.15 (1.95-2.36)	2.48 (2.26-2.74)	2.89 (2.31-3.61)	
Polarstem Cementless / R3 Cementless	8,543	66 (58-73)	46	0.60 (0.45-0.79)	0.93 (0.73-1.19)	0.97 (0.75-1.24)	0.97 (0.75-1.24)		
SL-Plus Cementless Stem / EP-Fit Plus	5,402	66 (59-73)	43	1.24 (0.97-1.57)	2.61 (2.21-3.09)	3.78 (3.27-4.35)	4.45 (3.89-5.08)	5.83 (5.14-6.62)	
Synergy Cementless Stem / R3 Cementless	3,348	65 (57-71)	51	0.97 (0.69-1.37)	1.42 (1.05-1.91)	1.95 (1.45-2.64)	3.50 (2.40-5.09)		
Taperloc Cementless Stem / Exceed ABT	22,851	65 (58-72)	44	1.07 (0.94-1.21)	1.52 (1.36-1.70)	1.83 (1.65-2.04)	2.12 (1.90-2.37)	2.16 (1.93-2.42)	
Anthology / R3 Cementless	4,042	63 (54-70)	42	1.13 (0.84-1.51)	1.60 (1.23-2.07)	2.30 (1.77-2.99)	3.57 (2.56-4.98)		
Metafix Stem / Trinity	4,403	64 (56-70)	46	0.80 (0.57-1.13)	1.44 (1.09-1.90)	1.80 (1.33-2.43)	1.80 (1.33-2.43)		
M/L Taper Cementless / Continuum	5,406	61 (53-68)	49	1.17 (0.92-1.50)	1.79 (1.45-2.20)	2.15 (1.74-2.64)	2.31 (1.86-2.87)		
M/L Taper Cementless / Trilogy IT	3,748	64 (55-70)	51	1.00 (0.72-1.38)	2.27 (1.75-2.93)	2.27 (1.75-2.93)			
Furlong Evolution Cementless / Furlong HAC CSF Plus	3,463	62 (52-70)	40	1.19 (0.87-1.63)	1.76 (1.31-2.35)	1.94 (1.45-2.61)			

Note: Blank cells indicate that the number at risk at the time shown has fallen below ten and thus estimates have been omitted as they are highly unreliable.

THA with very long-term survivorship

Results of a retrospectively reviewed 502 consecutive THRs performed at 3 centers between 2002 and 2005

The Kaplan-Meier Survivorship Estimate at 11.9 years follow-up was 98.7% (95% CI, 96.6-99.5) with revision of the dual mobility acetabular system for any reason as the endpoint

No dislocation

There were 15 revisions of the dual mobility acetabular component

- 14 for aseptic loosening

- 1 secondary to fracture of the femur



POLARCUP Dual Mobility System
(Smith & Nephew, Baar, Switzerland)

Conclusion

Cementless stem with Dual Mobility cup / oxynium / XLPE is for us the best choice for young patients

However we still need more evidents, and more registrer data

Thank You

Lunch symposium St Petersburg 28th Sept. 2018



www.groupegiles.org